- Summits
- Sponsorship
- News
- About
Gameto, a clinical-stage biotech and a TA Ventures portfolio company, has raised $44 million in a Series C round led by Overwater Ventures, with backing from Insight Partners, RA Capital, Two Sigma Ventures, and others. The new funding brings Gameto’s total capital raised to $127 million, placing it among the best-capitalized companies in reproductive health.
Founded by Dr. Dina Radenkovic, a medical doctor-turned-entrepreneur, and Martin Varsavsky, the founder of Inception Prelude, one of the largest fertility clinic chain in North America, Gameto is built on a cell engineering platform developed with George Church’s lab at Harvard Medical School. The company is focused on fertility, menopause, and broader women’s and family health.
The company’s lead program, Fertilo, is already in Phase 3 clinical trials. Fertilo is the first induced pluripotent stem cell (iPSC)-derived therapy to reach late-stage development in the United States, more than a decade after Shinya Yamanaka’s Nobel Prize-winning discovery of iPSC technology.
The therapy reimagines IVF by using engineered ovarian support cells to mature eggs outside the body, reducing the standard ovarian stimulation protocol from two weeks of daily hormone injections to just 2–3 days. Fertilo has already been cleared for use in multiple countries, including Mexico, Peru, Australia, and Japan. Five babies have been born with the therapy so far, with more than 20 pregnancies recorded.
“This is a defining moment for Gameto and for our broader mission of advancing women’s and family health,” said Dr. Dina Radenkovic Turner, CEO and Co-founder of Gameto. “With this fundraising round we are now positioned to complete our robust Phase 3 trial of Fertilo and evaluate its safety and efficacy across leading U.S. study sites.”
The FIRST trial, a randomized, controlled, double-blind study, is underway at leading fertility centers including Shady Grove Fertility, Columbia University, and Prelude Fertility. Interim results are expected in 2026.
The latest financing round reflects growing confidence in women’s health innovation—a space long underserved by biotech investment.
“We believe Gameto has the potential to drive the biggest transformation in women’s health since the birth control pill,” said Kristina Simmons, Founder and Managing Partner at Overwater Ventures. “We have yet to see another company with the rare combination of determination, breakthrough science, and the potential to create a strong consumer brand in biotech.”
This marks Overwater’s largest investment to date, signaling the scale of their conviction.
While Fertilo leads the pipeline, Gameto is also advancing therapies for menopause through its Ameno program. Supported by ARPA-H funding, the program includes an implantable cell therapy designed to restore ovarian hormone production, as well as a next-generation vaginal ring that mimics natural hormone cycles more closely than existing products.
“As someone who has built fertility clinic networks around the world, I know firsthand how urgently patients and physicians need better tools,” said Martin Varsavsky, Co-founder and Chairman of Gameto. “Fertilo has the potential to transform IVF, making it faster, safer, and more accessible to patients. This financing round marks a major step toward realizing that vision.”
With its AI-powered organoid models of the female reproductive system, Gameto is also exploring ways to accelerate drug discovery and safety testing, opening the door to broader applications in women’s health.
With strong investor backing, a landmark late-stage trial, and an expanding pipeline, Gameto is positioning itself as one of the most promising players in women’s health biotech. If successful, Fertilo could significantly change how fertility care is delivered and open new possibilities for managing reproductive health throughout a woman’s life.
Join us at MedTech Malta 2025 (12–14 November) to explore more breakthroughs like these, connect with industry leaders, and take part in one of the fastest-growing global MedTech gatherings. For speaker opportunities, startup pitches, and sponsorships, contact us at [email protected].
